{
    "organizations": [],
    "uuid": "950dd715aece44542e57986995ce5ae2790e5be8",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vtv-therapeutics-announces-topline/brief-vtv-therapeutics-announces-topline-results-from-the-first-steadfast-phase-3-study-evaluating-azeliragon-in-people-with-mild-alzheimers-disease-idUSFWN1RM0R5",
    "ord_in_thread": 0,
    "title": "BRIEF-Vtv Therapeutics Announces Topline Results From The First Steadfast Phase 3 Study Evaluating Azeliragon In People With Mild Alzheimer's Disease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9 (Reuters) - vTv Therapeutics Inc:\n* VTV THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE FIRST STEADFAST PHASE 3 STUDY EVALUATING AZELIRAGON IN PEOPLE WITH MILD ALZHEIMER’S DISEASE\n* VTV THERAPEUTICS INC - AZELIRAGON WAS GENERALLY WELL-TOLERATED IN STUDY\n* VTV THERAPEUTICS INC - PHASE 3 STEADFAST STUDY DID NOT MEET EITHER CO-PRIMARY EFFICACY ENDPOINT\n* VTV THERAPEUTICS - IS DISCONTINUING CURRENT CLINICAL STUDIES INVOLVING AZELIRAGON, INCLUDING OPEN-LABEL EXTENSION STUDY AND PART B OF STEADFAST STUDY​\n* VTV THERAPEUTICS - WILL CONTINUE TO EVALUATE SUBSET DATA FROM PART A AND DATASET FROM PART B OF STEADFAST STUDY OVER COMING WEEKS\n* VTV THERAPEUTICS - EXPECT SUBSTANTIAL PORTION OF PATIENTS IN PART B OF STEADFAST WILL HAVE COMPLETED 12 MONTHS OF TREATMENT UNDER STUDY PROTOCOL Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-10T04:52:00.000+03:00",
    "crawled": "2018-04-10T13:00:51.036+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "vtv",
        "therapeutic",
        "inc",
        "vtv",
        "therapeutic",
        "announces",
        "topline",
        "result",
        "first",
        "steadfast",
        "phase",
        "study",
        "evaluating",
        "azeliragon",
        "people",
        "mild",
        "alzheimer",
        "disease",
        "vtv",
        "therapeutic",
        "inc",
        "azeliragon",
        "generally",
        "study",
        "vtv",
        "therapeutic",
        "inc",
        "phase",
        "steadfast",
        "study",
        "meet",
        "either",
        "efficacy",
        "endpoint",
        "vtv",
        "therapeutic",
        "discontinuing",
        "current",
        "clinical",
        "study",
        "involving",
        "azeliragon",
        "including",
        "extension",
        "study",
        "part",
        "b",
        "steadfast",
        "vtv",
        "therapeutic",
        "continue",
        "evaluate",
        "subset",
        "data",
        "part",
        "dataset",
        "part",
        "b",
        "steadfast",
        "study",
        "coming",
        "week",
        "vtv",
        "therapeutic",
        "expect",
        "substantial",
        "portion",
        "patient",
        "part",
        "b",
        "steadfast",
        "completed",
        "month",
        "treatment",
        "study",
        "protocol",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}